The spread of artemisinin resistance, and subsequent ACT partner drug resistance, threatens malaria control in the Greater Mekong Subregion (GMS) and beyond. The spread of multidrug-resistant P. falciparum co-lineages to Africa, where most of the world’s malaria transmission, morbidity, and mortality occur, would be disastrous. Since new drugs are 5 years away, there is an urgent need to evaluate alternative treatments using existing drugs. A promising novel approach is the use of Triple ACTs (TACTs), which combine a short-acting artemisinin with two longer-acting partner drugs.Dr. Rob van der Pluijm will present the pre-final results of the large multinational, multicenter randomized clinical TRAC II trial, evaluating two TACTs.